Рубрики Mesh:
Пожилые
Пожилые 80-ти лет и старше
Андростены - прием и дозировка
Противоопухолевой комбинированной химиотерапии протоколы - прием и дозировка
Костей новообразования - лекарственная терапия
Костей новообразования - патология
Костей новообразования - вторичный
Человек
Мужской
Средний возраст
Новообразований метастазы
Предстательной железы новообразования кастрационно-резистентные - лекарственная терапия
Предстательной железы новообразования кастрационно-резистентные - патология
Трипторелина памоат - прием и дозировка
Журнальная статья
Rapoport L.M.
Bezrukov E.A.
Kondrashina A.V.
The Department of Urology of Medical Faculty, I.M. Sechenov First Moscow State Medical University of Minzdrav of Russia.
Concomitant use of abiraterone acetate and triptorelin in patients with castration-resistant prostate cancer
Текст визуальный электронный
Urologiia (Moscow, Russia : 1999)
№ 1 С. 58-61
2016
abiraterone acetate
castration-resistant prostate cancer
triptorelin
Статья
Aged M01.060.116.100
Пожилые M01.060.116.100
Aged, 80 and over M01.060.116.100.080
Пожилые 80-ти лет и старше M01.060.116.100.080
Androstenes administration & dosage D04.210.500.054.079
Андростены прием и дозировка D04.210.500.054.079
Antineoplastic Combined Chemotherapy Protocols administration & dosage E02.183.750.500 E02.319.077.500 E02.319.310.037
Противоопухолевой комбинированной химиотерапии протоколы прием и дозировка E02.183.750.500 E02.319.077.500 E02.319.310.037
Bone Neoplasms drug therapy C04.588.149 C05.116.231
Bone Neoplasms pathology C04.588.149 C05.116.231
Bone Neoplasms secondary C04.588.149 C05.116.231
Костей новообразования лекарственная терапия C04.588.149 C05.116.231
Костей новообразования патология C04.588.149 C05.116.231
Костей новообразования вторичный C04.588.149 C05.116.231
Humans B01.050.150.900.649.313.988.400.112.400.400
Человек B01.050.150.900.649.313.988.400.112.400.400
Male
Мужской
Middle Aged M01.060.116.630
Средний возраст M01.060.116.630
Neoplasm Metastasis C04.697.650 C23.550.727.650
Новообразований метастазы C04.697.650 C23.550.727.650
Prostatic Neoplasms, Castration-Resistant drug therapy C04.588.945.440.770.500 C12.100.500.260.750.500 C12.100.500.565.625.500 C12.200.294.260.750.500 C12.200.294.565.625.500 C12.200.758.409.750.500 C12.900.619.750.500
Prostatic Neoplasms, Castration-Resistant pathology C04.588.945.440.770.500 C12.100.500.260.750.500 C12.100.500.565.625.500 C12.200.294.260.750.500 C12.200.294.565.625.500 C12.200.758.409.750.500 C12.900.619.750.500
Предстательной железы новообразования кастрационно-резистентные лекарственная терапия C04.588.945.440.770.500 C12.100.500.260.750.500 C12.100.500.565.625.500 C12.200.294.260.750.500 C12.200.294.565.625.500 C12.200.758.409.750.500 C12.900.619.750.500
Предстательной железы новообразования кастрационно-резистентные патология C04.588.945.440.770.500 C12.100.500.260.750.500 C12.100.500.565.625.500 C12.200.294.260.750.500 C12.200.294.565.625.500 C12.200.758.409.750.500 C12.900.619.750.500
Triptorelin Pamoate administration & dosage D06.472.699.327.740.320.790 D12.644.400.400.740.320.790 D12.644.456.460.800 D12.644.548.365.740.320.790 D12.776.631.650.405.740.320.790
Трипторелина памоат прием и дозировка D06.472.699.327.740.320.790 D12.644.400.400.740.320.790 D12.644.456.460.800 D12.644.548.365.740.320.790 D12.776.631.650.405.740.320.790
Journal Article V02.600
Журнальная статья V02.600
abiraterone
The relevance of drug treatment for prostate cancer increases with the number of patients who develop castration resistance. Currently, no unified treatment regimen for castration-resistant prostate cancer exists, but the standard treatment for these patients is continuous androgen deprivation therapy. This paper presents the experience of concomitant use of abiraterone acetate and triptorelin in patients with castration-resistant prostate cancer. Ten patients with disease duration of 1.5 to 18 years and established castration resistance are currently being followed up. Nine of ten patients have long-term bone metastases, one patient has visceral metastases. The combination therapy produced a significant PSA decrease in nine patients and regression of bone lesions in two patients.